A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 17, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Solid Tumor, Adult
Interventions
BIOLOGICAL

Bio-008

The subjects in each dose group received the corresponding dose of BIO-008 monotherapy, administered intravenously (ivd) for a duration of 0.5 to 3 hours (the researchers can adjust the administration time according to the patient's tolerance). If there is an infusion reaction, the infusion can be suspended and completed within 12 hours. Administer on the first day of each cycle, once every 3 weeks (1 cycle, i.e. 21 days) (Q3W) until the criteria for termination of treatment or withdrawal from the study are met, whichever occurs first.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of the Chinese People's Liberation Army Air Force Military Medical University, Xi'an

All Listed Sponsors
lead

Shijiazhuang Yiling Pharmaceutical Co. Ltd

INDUSTRY